Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV2-CB-hRPE65 in Leber Congenital Amaurosis Type 2
NCT00749957Phase 2Completed
- Sponsor
- Beacon Therapeutics
- Start
- Jun 2009
- Primary completion
- Sep 2014
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of rAAV2-CB-hRPE65 in Leber congenital amaurosis type 2 (LCA2), sponsored by Beacon Therapeutics. Started Jun 2009; status: completed.
02
Drugs
rAAV2-CB-hRPE65
03
Conditions
Leber congenital amaurosis type 2 (LCA2)
Beyond the preview
Go deeper on NCT00749957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00749957.